Harnessing self-assembled peptide nanoparticles in epitope vaccine design

Negahdaripour, Manica; Golkar, Nasim; Hajighahramani, Nasim; Kianpour, Sedigheh; Nezafat, Navid

doi:10.1016/j.biotechadv.2017.05.002

Cited by 107 publications

(88 citation statements)

References 247 publications

(290 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As nanoparticles have been shown to have promising self-adjuvanting properties (12,13), amphiphiles that self-assemble into them are often used in peptide vaccine delivery (14)(15)(16). For example, hydrophobic dendritic poly(tert-butyl acrylate) has previously been conjugated to a variety of peptide epitopes, including GAS-derived peptides, and the conjugates have been self-assembled to form particles (17).…”

Section: Introductionmentioning

confidence: 99%

Poly(amino acids) as a potent self-adjuvanting delivery system for peptide-based nanovaccines

et al. 2020

View full text Add to dashboard Cite

To be optimally effective, peptide-based vaccines need to be administered with adjuvants. Many currently available adjuvants are toxic, not biodegradable; they invariably invoke adverse reactions, including allergic responses and excessive inflammation. A nontoxic, biodegradable, biocompatible, self-adjuvanting vaccine delivery system is urgently needed. Herein, we report a potent vaccine delivery system fulfilling the above requirements. A peptide antigen was coupled with poly-hydrophobic amino acid sequences serving as self-adjuvanting moieties using solid-phase synthesis, to produce fully defined single molecular entities. Under aqueous conditions, these molecules self-assembled into distinct nanoparticles and chain-like aggregates. Following subcutaneous immunization in mice, these particles successfully induced opsonic epitope-specific antibodies without the need of external adjuvant. Mice immunized with entities bearing 15 leucine residues were able to clear bacterial load from target organs without triggering the release of soluble inflammatory mediators. Thus, we have developed a well-defined and effective self-adjuvanting delivery system for peptide antigens.

show abstract

Section: Introductionmentioning

confidence: 99%

Poly(amino acids) as a potent self-adjuvanting delivery system for peptide-based nanovaccines

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Coiled-coil motifs, due to their high stability and well-defined structures have gained more attention in developing SAPN vaccine [60]. In recent years, because of unique characterizations of SAPN, including biodegradability, biocompatibility, size similarity to pathogen [61], self-adjuvanticity, and containing repetitive structure [62], they have been proposed as prominent structure in designing epitope-based peptide vaccine [10,63]. Each SAPN monomer, the subunit that oligomerizes to form the nanoparticle, contains two coiled-coil domains fused together by proper linkers, which are able to oligomerize, and consequently, form nanoparticles.…”

Section: Discussionmentioning

confidence: 99%

“…In general, the majority of epitope-based vaccines can cause induction of cellular or/and humoral immunity as well as offer a safer and more easy-produced alternative for the prevention of diseases; however, the low immunogenicity is the main disadvantage of such types of vaccines. For solving this problem, several methods have been used to enhance the immunogenicity epitopes vaccines, like prescribing the multiple doses of vaccine, adding immunostimulatory agents such an adjuvant to the vaccine [9], and the recent strategy is applying self-assembled peptide motif including betasheets or coiled-coil structures in the epitope vaccine [10]. Besides above-mentioned strategies, incorporating universal T-helper epitopes like diphtheria toxoids (DTD) into vaccine can enhance vaccine efficacy.…”

Section: Introductionmentioning

confidence: 99%

Designing self-assembled peptide nanovaccine against Streptococcus pneumoniae: An in silico strategy

Dorosti

Eslami

Nezafat

et al. 2019

Molecular and Cellular Probes

Self Cite

View full text Add to dashboard Cite

A B S T R A C TStreptococcus pneumoniae is the main cause of diseases such as meningitis, pneumoniae and sepsis, especially in children and old people. Due to costly antibiotic treatment, and increasing resistance of pneumococcus, developing high-efficient protective vaccine against this pathogen is an urgent need. Although the pneumoniae polysaccharide vaccine (PPV) and pneumonia conjugate vaccines (PCV) are the efficient pneumococcal vaccine in children and adult groups, but the serotype replacement of S. pneumoniae strains causes the reduction in efficacy of such vaccines. For overcoming the aforesaid drawbacks epitope-based vaccines are introduced as the relevant alternative. In our previous research, the epitope vaccine was designed based on immunodominant epitopes from PspA, CbpA antigens as cellular stimulants and PhtD, PiuA as humoral stimulants. Because the low immunogenicity is the main disadvantage of epitope vaccine, in the current study, we applied coiled-coil selfassembled structures for developing our vaccine. Recently, self-assembled peptide nanoparticles (SAPNs) have gained much attention in the field of vaccine development due to their multivalency, self-adjuvanticity, biocompatibility, and size similarity to pathogen. In this regard, the final designed vaccine is comprised of cytotoxic T lymphocytes (CTL) epitopes from PspA and CbpA, helper T lymphocytes (HTL) epitopes from PhtD and PiuA, the pentamer and trimmer oligomeric domains form 5-stranded and 3-stranded coiled-coils as self-assembled scaffold, Diphtheria toxoids (DTD) as a universal T-helper, which fused to each other with appropriate linkers. The four different arrangements based on the order of above-mentioned compartments were constructed, and each of them were modeled, and validated to find the 3D structure. The structural, physicochemical, and immunoinformatics analyses of final vaccine construct represented that our vaccine could stimulate potent immune response against S. pneumoniae; however, the potency of that should be approved via various in vivo and in vitro immunological tests.

show abstract

“…With the rapid advances in nanotechnology, nanoparticlecarried vaccines have emerged as novel approaches to vaccine design, and their use in peptide-based tolerogenic vaccinations has gained increasing concerns in recent years [19,92]. Nanoparticles coated with tolerogenic antigen peptides is a novel and promising strategy for inducing antigen-specific immune tolerance, which may promote the application of peptide-based vaccination in rheumatic diseases.…”

Section: Journal Of Immunology Researchmentioning

confidence: 99%

Peptide-Based Vaccination Therapy for Rheumatic Diseases

Wang

Chen

Zheng

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Rheumatic diseases are extremely heterogeneous diseases with substantial risks of morbidity and mortality, and there is a pressing need in developing more safe and cost-effective treatment strategies. Peptide-based vaccination is a highly desirable strategy in treating noninfection diseases, such as cancer and autoimmune diseases, and has gained increasing attentions. This review is aimed at providing a brief overview of the recent advances in peptide-based vaccination therapy for rheumatic diseases. Tremendous efforts have been made to develop effective peptide-based vaccinations against rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), while studies in other rheumatic diseases are still limited. Peptide-based active vaccination against pathogenic cytokines such as TNF-α and interferon-α (IFN-α) is shown to be promising in treating RA or SLE. Moreover, peptide-based tolerogenic vaccinations also have encouraging results in treating RA or SLE. However, most studies available now have been mainly based on animal models, while evidence from clinical studies is still lacking. The translation of these advances from experimental studies into clinical therapy remains impeded by some obstacles such as species difference in immunity, disease heterogeneity, and lack of safe delivery carriers or adjuvants. Nevertheless, advances in high-throughput technology, bioinformatics, and nanotechnology may help overcome these impediments and facilitate the successful development of peptide-based vaccination therapy for rheumatic diseases.

show abstract

Harnessing self-assembled peptide nanoparticles in epitope vaccine design

Cited by 107 publications

References 247 publications

Poly(amino acids) as a potent self-adjuvanting delivery system for peptide-based nanovaccines

Poly(amino acids) as a potent self-adjuvanting delivery system for peptide-based nanovaccines

Designing self-assembled peptide nanovaccine against Streptococcus pneumoniae: An in silico strategy

Peptide-Based Vaccination Therapy for Rheumatic Diseases

Contact Info

Product

Resources

About